Table 3.

Summary of toxicity experienced by at least 10% of patients (any grade) or 2% or more of patients (for grade 3 or higher). All adverse events are at least possibly attributed to cixutumumab

Toxicity	All grades (n=49)	Grade 1–2 (n=49)	Grade 3 (n=49)	Grade 4 (n=49)	Grade 5 (n=49)
Alanine aminotransferase increased	3 (6%)	2 (4%)	1 (2%)	0	0
Alopecia	5 (10%)	5 (10%)	0	0	0
Anemia	5 (10%)	5 (10%)	0	0	0
Anorexia	17 (35%)	17 (35%)	0	0	0
Aspartate aminotransferase increased	4 (8%)	3 (6%)	1 (2%)	0	0
Creatine kinase increased	1 (2%)	0	0	1 (2%)	0
Creatinine increased	12 (25%)	12 (25%)	0	0	0
Dyspnea	1 (2%)	0	0	1 (2%)	0
Fatigue	14 (29%)	13 (27%)	1 (2%)	0	0
Hyperglycemia	26 (53%)	21 (43%)	5 (10%)	0	0
Hyperuricemia	19 (39%)	17 (35%)	0	2 (4%)	0
Lipase increased	4 (8%)	1 (2%)	3 (6%)	0	0
Muscle cramps	14 (29%)	14 (29%)	0	0	0
Myositis	1 (2%)	0	1 (2%)	0	0
Nail changes (nail loss, nail splitting, brittle nails, nail discoloration)	7 (14%)	7 (14%)	0	0	0
Nausea	8 (16%)	8 (16%)	0	0	0
Oral mucositis/ulceration	7 (14%)	7 (14%)	0	0	0
Respiratory failure	1 (2%)	0	0	0	1 (2%)
Thrombocytopenia	7 (14%)	7 (14%)	0	0	0
Tumor pain	8 (16%)	6 (12%)	2 (4%)	0	0
Visual changes (blurred vision, floaters, flashing lights)	7 (14%)	7 (14%)	0	0	0
Weight loss	5 (10%)	3 (6%)	2 (4%)	0	0

Data are number of patients (%). Events are maximum grade per patient, over all cycles.